Cargando…

Contrast Enhancement on Cone-Beam Breast-CT for Discrimination of Breast Cancer Immunohistochemical Subtypes()()()

PURPOSE: To evaluate whether contrast enhancement on cone-beam breast-CT (CBBCT) could aid in discrimination of breast cancer subtypes and receptor status. METHODS: This study included female patients age >40 years with malignant breast lesions identified on contrast-enhanced CBBCT. Contrast enha...

Descripción completa

Detalles Bibliográficos
Autores principales: Uhlig, Johannes, Fischer, Uwe, von Fintel, Eva, Stahnke, Vera, Perske, Christina, Lotz, Joachim, Wienbeck, Susanne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5614638/
https://www.ncbi.nlm.nih.gov/pubmed/28946110
http://dx.doi.org/10.1016/j.tranon.2017.08.010
_version_ 1783266435242393600
author Uhlig, Johannes
Fischer, Uwe
von Fintel, Eva
Stahnke, Vera
Perske, Christina
Lotz, Joachim
Wienbeck, Susanne
author_facet Uhlig, Johannes
Fischer, Uwe
von Fintel, Eva
Stahnke, Vera
Perske, Christina
Lotz, Joachim
Wienbeck, Susanne
author_sort Uhlig, Johannes
collection PubMed
description PURPOSE: To evaluate whether contrast enhancement on cone-beam breast-CT (CBBCT) could aid in discrimination of breast cancer subtypes and receptor status. METHODS: This study included female patients age >40 years with malignant breast lesions identified on contrast-enhanced CBBCT. Contrast enhancement of malignant breast lesions was standardized to breast fat tissue contrast enhancement. All breast lesions were approved via image-guided biopsy or surgery. Immunohistochemical staining was conducted for expression of estrogen (ER), progesterone (PR), human epidermal growth factor receptor-2 (HER2) and Ki-67 index. Contrast enhancement of breast lesions was correlated with immunohistochemical breast cancer subtypes (Luminal A, Luminal B, HER2 positive, triple negative), receptor status and Ki-67 expression. RESULTS: Highest contrast enhancement was seen for Luminal A lesions (93.6 HU) compared to Luminal B lesions (47.6 HU, P = .002), HER2 positive lesions (83.5 HU, P = .359) and triple negative lesions (45.3 HU, P = .005). Contrast enhancement of HER2 positive lesions was higher than Luminal B lesions (P = .044) and triple negative lesions (P = .039). No significant difference was evident between Luminal B and triple negative lesions (P = .439). Lesions with high Ki-67 index showed lower contrast enhancement than those with low Ki-67 index (P = .0043). ER, PR and HER2 positive lesions demonstrated higher contrast enhancement than their receptor negative counterparts, although differences did not reach statistical significance (P = .1714; P = .3603; P = .2166). CONCLUSIONS: Contrast enhancement of malignant breast lesions on CBBCT correlates with immunohistochemical subtype and proliferative potential. Thereby, CBBCT might aid in selecting individualized treatment strategies for breast cancer patients based on pre-operative imaging.
format Online
Article
Text
id pubmed-5614638
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Neoplasia Press
record_format MEDLINE/PubMed
spelling pubmed-56146382017-10-02 Contrast Enhancement on Cone-Beam Breast-CT for Discrimination of Breast Cancer Immunohistochemical Subtypes()()() Uhlig, Johannes Fischer, Uwe von Fintel, Eva Stahnke, Vera Perske, Christina Lotz, Joachim Wienbeck, Susanne Transl Oncol Original article PURPOSE: To evaluate whether contrast enhancement on cone-beam breast-CT (CBBCT) could aid in discrimination of breast cancer subtypes and receptor status. METHODS: This study included female patients age >40 years with malignant breast lesions identified on contrast-enhanced CBBCT. Contrast enhancement of malignant breast lesions was standardized to breast fat tissue contrast enhancement. All breast lesions were approved via image-guided biopsy or surgery. Immunohistochemical staining was conducted for expression of estrogen (ER), progesterone (PR), human epidermal growth factor receptor-2 (HER2) and Ki-67 index. Contrast enhancement of breast lesions was correlated with immunohistochemical breast cancer subtypes (Luminal A, Luminal B, HER2 positive, triple negative), receptor status and Ki-67 expression. RESULTS: Highest contrast enhancement was seen for Luminal A lesions (93.6 HU) compared to Luminal B lesions (47.6 HU, P = .002), HER2 positive lesions (83.5 HU, P = .359) and triple negative lesions (45.3 HU, P = .005). Contrast enhancement of HER2 positive lesions was higher than Luminal B lesions (P = .044) and triple negative lesions (P = .039). No significant difference was evident between Luminal B and triple negative lesions (P = .439). Lesions with high Ki-67 index showed lower contrast enhancement than those with low Ki-67 index (P = .0043). ER, PR and HER2 positive lesions demonstrated higher contrast enhancement than their receptor negative counterparts, although differences did not reach statistical significance (P = .1714; P = .3603; P = .2166). CONCLUSIONS: Contrast enhancement of malignant breast lesions on CBBCT correlates with immunohistochemical subtype and proliferative potential. Thereby, CBBCT might aid in selecting individualized treatment strategies for breast cancer patients based on pre-operative imaging. Neoplasia Press 2017-09-22 /pmc/articles/PMC5614638/ /pubmed/28946110 http://dx.doi.org/10.1016/j.tranon.2017.08.010 Text en © 2017 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original article
Uhlig, Johannes
Fischer, Uwe
von Fintel, Eva
Stahnke, Vera
Perske, Christina
Lotz, Joachim
Wienbeck, Susanne
Contrast Enhancement on Cone-Beam Breast-CT for Discrimination of Breast Cancer Immunohistochemical Subtypes()()()
title Contrast Enhancement on Cone-Beam Breast-CT for Discrimination of Breast Cancer Immunohistochemical Subtypes()()()
title_full Contrast Enhancement on Cone-Beam Breast-CT for Discrimination of Breast Cancer Immunohistochemical Subtypes()()()
title_fullStr Contrast Enhancement on Cone-Beam Breast-CT for Discrimination of Breast Cancer Immunohistochemical Subtypes()()()
title_full_unstemmed Contrast Enhancement on Cone-Beam Breast-CT for Discrimination of Breast Cancer Immunohistochemical Subtypes()()()
title_short Contrast Enhancement on Cone-Beam Breast-CT for Discrimination of Breast Cancer Immunohistochemical Subtypes()()()
title_sort contrast enhancement on cone-beam breast-ct for discrimination of breast cancer immunohistochemical subtypes()()()
topic Original article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5614638/
https://www.ncbi.nlm.nih.gov/pubmed/28946110
http://dx.doi.org/10.1016/j.tranon.2017.08.010
work_keys_str_mv AT uhligjohannes contrastenhancementonconebeambreastctfordiscriminationofbreastcancerimmunohistochemicalsubtypes
AT fischeruwe contrastenhancementonconebeambreastctfordiscriminationofbreastcancerimmunohistochemicalsubtypes
AT vonfinteleva contrastenhancementonconebeambreastctfordiscriminationofbreastcancerimmunohistochemicalsubtypes
AT stahnkevera contrastenhancementonconebeambreastctfordiscriminationofbreastcancerimmunohistochemicalsubtypes
AT perskechristina contrastenhancementonconebeambreastctfordiscriminationofbreastcancerimmunohistochemicalsubtypes
AT lotzjoachim contrastenhancementonconebeambreastctfordiscriminationofbreastcancerimmunohistochemicalsubtypes
AT wienbecksusanne contrastenhancementonconebeambreastctfordiscriminationofbreastcancerimmunohistochemicalsubtypes